Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.
The prognosis of patients with systemic lupus erythematosus has greatly improved since treatment regimens combining corticosteroids and immunosuppressive medications have been widely adopted in therapeutic strategies given to these patients. Immune suppression is evidently efficient but also leads to higher susceptibility to infectious and malignant diseases. Toxic effects and sometimes unexpectedly dramatic complications of current therapies have been progressively reported. Identifying novel molecular targets therefore remains an important issue in the treatment of lupus. The aim of this review article is to highlight emerging pharmacological options and new therapeutic avenues for lupus with a particular focus on non-antibody molecular strategies.
Monneaux
Fanny
F
CNRS, Immunologie et Chimie Thérapeutiques, Institut de Biologie Moléculaire et Cellulaire, 67000 Strasbourg, France. F.Monneaux@ibmc.u-strasbg.fr
Muller
Sylviane
S
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends*; D005544:Forecasting; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology